Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

(2016) Nick Pavlakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma

(2015) Martin J.B. Taphoorn et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-VEGF Molecular Targeted Therapies in Common Solid Malignancies: Comprehensive Update for Radiologists

(2015) Sree Harsha Tirumani et al.   RADIOGRAPHICS

Benefits and Risks of Lung Cancer Screening

(2014) Karl-Matthias Deppermann et al.   Oncology Research and Treatment

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis

(2013) H. S. Kim et al.   ANNALS OF ONCOLOGY

Prevention and management of adverse events related to regorafenib

(2013) Mieke De Wit et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall andKRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial

(2009) Heather-Jane Au et al.   JOURNAL OF CLINICAL ONCOLOGY

Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy

(2008) Se Hoon Park et al.   QUALITY OF LIFE RESEARCH